163 related articles for article (PubMed ID: 20431031)
1. A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide.
Denys B; El Housni H; Nollet F; Verhasselt B; Philippé J
J Mol Diagn; 2010 Jul; 12(4):512-9. PubMed ID: 20431031
[TBL] [Abstract][Full Text] [Related]
2. Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide.
Huijsmans CJ; Poodt J; Savelkoul PH; Hermans MH
J Mol Diagn; 2011 Sep; 13(5):558-64. PubMed ID: 21723417
[TBL] [Abstract][Full Text] [Related]
3. [A novel modi cation of real-time AS-qPCR by using locked nucleic acid-modified oligonucleotide probe as wild type allele amplification blockers for quantitative detection of the JAK2 V617F mutation].
Shao DH; Liang GW; He ML; Cao QY
Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):421-5. PubMed ID: 23688754
[TBL] [Abstract][Full Text] [Related]
4. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
[TBL] [Abstract][Full Text] [Related]
5. A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms.
Minnucci G; Amicarelli G; Salmoiraghi S; Spinelli O; Guinea Montalvo ML; Giussani U; Adlerstein D; Rambaldi A
Haematologica; 2012 Sep; 97(9):1394-400. PubMed ID: 22315499
[TBL] [Abstract][Full Text] [Related]
6. [Detection of JAK2V617F mutation rate by real-time fluorescent quantitative PCR using allele specific primer and TaqMan-MGB probe for dual inhibiting amplification of wild type alleles].
Liang GW; Shao DH; He ML; Cao QY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1486-91. PubMed ID: 23257459
[TBL] [Abstract][Full Text] [Related]
7. Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms.
Hu L; Pu L; Ding Y; Li M; Cabanero M; Xie J; Zhou D; Yang D; Zhang C; Wang H; Zhai Z; Ru X; Li J; Xiong S
Hematology; 2017 Jul; 22(6):354-360. PubMed ID: 27976991
[TBL] [Abstract][Full Text] [Related]
8. Melting curve analysis after T allele enrichment (MelcaTle) as a highly sensitive and reliable method for detecting the JAK2V617F mutation.
Morishita S; Takahashi K; Araki M; Hironaka Y; Sunami Y; Edahiro Y; Tsutsui M; Ohsaka A; Tsuneda S; Komatsu N
PLoS One; 2015; 10(3):e0122003. PubMed ID: 25794279
[TBL] [Abstract][Full Text] [Related]
9. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.
Lippert E; Girodon F; Hammond E; Jelinek J; Reading NS; Fehse B; Hanlon K; Hermans M; Richard C; Swierczek S; Ugo V; Carillo S; Harrivel V; Marzac C; Pietra D; Sobas M; Mounier M; Migeon M; Ellard S; Kröger N; Herrmann R; Prchal JT; Skoda RC; Hermouet S
Haematologica; 2009 Jan; 94(1):38-45. PubMed ID: 19001280
[TBL] [Abstract][Full Text] [Related]
10. Alternately binding probe competitive PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in myeloproliferative neoplasms.
Morishita S; Komatsu N; Kirito K; Koda AH; Sekiguchi Y; Tsuneda S; Noda N
Leuk Res; 2011 Dec; 35(12):1632-6. PubMed ID: 21752468
[TBL] [Abstract][Full Text] [Related]
11. Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation.
Morandi L; de Biase D; Visani M; Cesari V; De Maglio G; Pizzolitto S; Pession A; Tallini G
PLoS One; 2012; 7(4):e36084. PubMed ID: 22558339
[TBL] [Abstract][Full Text] [Related]
12. Single nucleotide polymorphism (SNP)-based loss of heterozygosity (LOH) testing by real time PCR in patients suspect of myeloproliferative disease.
Huijsmans CJ; Poodt J; Damen J; van der Linden JC; Savelkoul PH; Pruijt JF; Hilbink M; Hermans MH
PLoS One; 2012; 7(7):e38362. PubMed ID: 22768290
[TBL] [Abstract][Full Text] [Related]
13. Development of a highly sensitive method for detection of JAK2V617F.
Zhao AH; Gao R; Zhao ZJ
J Hematol Oncol; 2011 Oct; 4():40. PubMed ID: 21985400
[TBL] [Abstract][Full Text] [Related]
14. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
15. A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.
Pancrazzi A; Guglielmelli P; Ponziani V; Bergamaschi G; Bosi A; Barosi G; Vannucchi AM
J Mol Diagn; 2008 Sep; 10(5):435-41. PubMed ID: 18669880
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.
Perricone M; Palandri F; Ottaviani E; Angelini M; Bagli L; Bellesia E; Donati M; Gemmati D; Zucchini P; Mancini S; Marchica V; Trubini S; De Matteis G; Di Zacomo S; Favarato M; Fioroni A; Bolzonella C; Maccari G; Navaglia F; Gatti D; Toffolatti L; Orlandi L; Laloux V; Manfrini M; Galieni P; Giannini B; Tieghi A; Barulli S; Serino ML; Maccaferri M; Scortechini AR; Giuliani N; Vallisa D; Bonifacio M; Accorsi P; Salbe C; Fazio V; Gusella M; Toffoletti E; Salvucci M; Svaldi M; Gherlinzoni F; Cassavia F; Orsini F; Martinelli G
Oncotarget; 2017 May; 8(20):32608-32617. PubMed ID: 28427233
[TBL] [Abstract][Full Text] [Related]
17. Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
Chen P; Ouyang J; Liang J; Yu X; Huang B
Clin Lab; 2016 Aug; 62(8):1477-1481. PubMed ID: 28164603
[TBL] [Abstract][Full Text] [Related]
18. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
[TBL] [Abstract][Full Text] [Related]
19. [Detection of JAK2V617F mutation in patients with myeloproliferative disorders with TaqMan-MGB probe].
Ruan GR; Chen SS; Li LD; Liu YR; Qin YZ; Li JL; Ma X; Wang FR; Jiang Q; Jiang B; Liu KY; Huang XJ
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2401-4. PubMed ID: 18036317
[TBL] [Abstract][Full Text] [Related]
20. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
